Wolverine Peptide Stack: Benefits, Dosage, Protocol, & More (2026)

Written by Wolverine Peptide Stack Editorial Team | Last updated:

September 11, 2026

The Wolverine Peptide Stack combines BPC-157 and TB-500, two research peptides frequently discussed for injury recovery and tissue repair. Its nickname comes from the comic-book character known for rapid healing.

The scientific interest is real, but the evidence needs context. A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 35 preclinical studies and just one clinical study, based on its search through June 2024. Animal and laboratory findings should not be read as established benefits for people.¹

This guide explains the proposed mechanisms, potential benefits, results claims, dosage questions, and practical limitations—so you can separate what researchers have observed from what remains uncertain.

Big Picture Summary

🧬 What it is: A combination of BPC-157 and TB-500, marketed around recovery and soft-tissue repair.
🔍 How it may work: Researchers are exploring effects on cell movement, blood-vessel signaling, and tissue remodeling.
🛠️ BPC-157 research: Much of the interest comes from experimental tendon, ligament, muscle, and gastrointestinal studies.
⚙️ TB-500 research: Check the molecule carefully. Analytical research identified TB-500 as an acetylated fragment of thymosin beta-4; the fragment and full-length protein are not interchangeable.²
💪 Potential benefits: The sections below explain the research behind recovery claims and where the evidence stops.
📊 At a glance: Comparison tables summarize common descriptions; the surrounding text explains their limitations.
📅 Results timeline: There is no established week-by-week recovery schedule for the commercial blend.
🗣️ Reviews and testimonials: Personal reports can raise useful questions, but cannot establish that a peptide caused an improvement.
💉 Dosage and handling: An online protocol or vial label does not establish a safe human treatment regimen.
❓ Common questions: Jump to the FAQ for concise answers and links to our more detailed guides.

Table of Contents

What Is the Wolverine Peptide Stack?

The Wolverine Stack is a name used for products or protocols combining two peptides. It is not the name of one standardized clinical formulation.

BPC-157: A synthetic peptide made up of 15 amino acids, studied for its effects on tissue repair and protective cellular responses.³
TB-500: A name associated with a synthetic fragment of thymosin beta-4. A published chemical analysis identified the acetylated sequence Ac-LKKTETQ in a TB-500 product.²
The combination: Intended to bring together repair-related mechanisms. Whether that translates into better outcomes must be tested rather than assumed.

Why the exact ingredient matters: A paper studying full-length thymosin beta-4, a short fragment, or a particular pharmaceutical formulation may not describe the material in a product marketed as “TB-500.” Read the methods and product specifications, not just the name.

How Does the Wolverine Peptide Stack Work?

The proposed rationale is that the components may influence different parts of tissue repair. The strongest way to understand that idea is to look at the individual mechanisms and the models in which they were studied.

BPC-157: Tendon and Tissue-Repair Research

BPC-157 attracts interest because of findings involving connective-tissue cells, blood vessels, and repair signaling. Here are four mechanisms commonly discussed:

Cell movement: In rat tendon explants and cultured tendon fibroblasts, BPC-157 increased cell outgrowth, migration, and survival under oxidative stress. The researchers linked these effects to FAK–paxillin signaling.³
Growth-factor sensitivity: A separate rat tendon-cell study found increased growth hormone receptor expression and a stronger proliferation response when growth hormone was added. This does not establish that BPC-157 raises growth hormone levels in people.⁴
Blood-vessel signaling: Experiments in cells and animal models linked BPC-157 to VEGFR2 activation and angiogenesis—the formation of new blood vessels.⁵
Nitric oxide pathways: Experiments using isolated rat aortas and vascular cells found effects on nitric oxide production and vessel relaxation.⁶

What that means: These findings provide hypotheses about repair biology. They do not prove that an injection selectively targets an injured tendon or produces a predictable recovery outcome.

👉 Explore the mechanisms and evidence in our comprehensive BPC-157 guide.

TB-500: Thymosin Beta-4 and Fragment Research

Much of the discussion around TB-500 draws on the broader thymosin beta-4 literature. That literature includes several interesting findings, but the distinction between molecules is essential.

Wound repair: Full-length thymosin beta-4 improved aspects of skin-wound healing in diabetic and aged mice. An unacetylated seven-amino-acid fragment also promoted repair in aged mice.⁷
Angiogenesis: Laboratory work identified the actin-binding region as important to thymosin beta-4’s effects on endothelial migration and vessel sprouting.⁸
Tissue remodeling: A corneal epithelial-cell study found that matrix metalloproteinase activity was necessary for thymosin beta-4 to promote cell migration.⁹
Fragment metabolism: A 2024 study examined TB-500 and its metabolites. In its fibroblast wound-healing assay, a metabolite—not the parent compound—showed significant activity versus control.¹⁰

These experiments help explain the research interest. They do not establish whole-body recovery, improved flexibility, or injury healing from a commercial TB-500 blend.

👉 Read our in-depth TB-500 guide for more background.

BPC-157 Vs. TB-500: Side-by-Side Comparison

How to read this comparison: Labels such as “targeted repair” and “broader recovery” summarize common descriptions. They are not clinically established divisions of how these peptides act in people.

Comparison Point	BPC-157	TB-500
Primary Role	Targeted repair	Broader recovery
Best Known For	Tendons, ligaments, joints	Mobility, flexibility, soft tissue
Recovery Style	Localized support	Systemic support
Common Focus	Inflammation, gut, connective tissue	Cell migration, tissue remodeling
Role in Wolverine Stack	Repair peptide	Recovery amplifier

The more useful comparison is the exact compound, study model, measured outcome, and strength of evidence. Neither a mechanism diagram nor a table demonstrates that the combination outperforms either component.

Does Combining Them Work Better?

A 2026 exploratory study compared BPC-157, a preparation described by the authors as TB-500, their combination, and a control in 32 rats after Achilles tendon repair. It found improved tissue parameters in treated groups, but did not demonstrate an additive benefit from the combination.¹¹

“The absence of additive effects with combination therapy may reflect convergence on shared downstream pathways”

Biçer and colleagues, 2026 rat Achilles tendon study.¹¹

That is one animal experiment, not a final answer for people. It is nevertheless a reason to describe “synergy” as a hypothesis, rather than an established advantage.

👉 See our guide on how the Wolverine Stack works and our comparison of the Wolverine Stack versus single peptides.

Wolverine Peptide Benefits

People usually research this blend because of persistent pain, a difficult recovery, or an injury that interferes with training. The main topics are:

Soft-tissue repair after injury.
Tendon and ligament healing.
Muscle recovery and return to activity.
Inflammation-related symptoms.
Joint comfort and mobility.

Evidence note: The table below summarizes areas of interest and commonly proposed effects. These are not confirmed treatment benefits of the Wolverine Stack in humans.

Benefit	Main Peptide Involved	What It May Support
Soft tissue repair	BPC-157 / TB-500	Muscles, tendons, ligaments, and connective tissue
Tendon and ligament support	BPC-157	Localized repair and connective tissue recovery
Muscle recovery	TB-500 / BPC-157	Recovery from training, strain, and physical stress
Inflammation response	BPC-157 / TB-500	Comfort, mobility, and a healthier repair environment
Joint comfort and mobility	BPC-157 / TB-500	Movement, flexibility, and recovery support
Overall recovery support	BPC-157 / TB-500	Broader repair and tissue remodeling processes

Soft Tissue Repair

One reason BPC-157 receives attention is that researchers have measured changes in wound closure and tissue organization, rather than relying only on symptom reports.

What was studied: An alkali-burn model in rats, alongside cell experiments.
What was observed: Topical BPC-157 accelerated wound closure and improved measures of tissue formation and collagen deposition.
What remains uncertain: Whether an injectable blend provides comparable benefits for common human soft-tissue injuries.¹²

Tendon and Ligament Support

These are among the most directly relevant areas of BPC-157 research:

Achilles tendon: A rat transection study reported improvements in mechanical strength, function, and tissue appearance with BPC-157.¹³
Medial collateral ligament: A separate rat study reported functional, biomechanical, and histological improvements after ligament transection.¹⁴
Clinical relevance: Surgically created injuries in rats are different from chronic tendinopathy, partial tears, or rehabilitation after surgery in people.

These findings justify further investigation. They do not establish that a peptide can replace rehabilitation or repair a torn human ligament.

Muscle Recovery

In a rat study involving complete quadriceps transection, BPC-157 improved several measures of muscle healing and function over the observation period.¹⁵

However, three different questions are often mixed together:

Repairing an injured muscle.
Reducing ordinary post-workout soreness.
Increasing muscle size or athletic performance.

An experiment addressing the first question does not automatically answer the other two. Claims about faster gym recovery or muscle growth need their own human evidence.

Inflammation Response

Inflammation-related mechanisms are part of the research discussion, but a change in a laboratory marker is different from a demonstrated improvement in a patient’s pain or function.

Vascular effects: BPC-157 has been studied in nitric oxide signaling and vessel-function experiments.⁶
Gastrointestinal protection: A review discusses experimental BPC-157 findings involving NSAID-related injury and intestinal permeability. It does not establish a treatment for human digestive symptoms.¹⁶
Practical interpretation: “Anti-inflammatory” should not be treated as a guarantee of pain relief or injury resolution.

Joint Comfort and Mobility

A small retrospective knee-pain report is often cited as human evidence. Among 16 patients reached for follow-up, 12 had received BPC-157 alone and four had received BPC-157 with thymosin beta-4.¹⁷

Why interpret it cautiously?

There was no randomized placebo comparison.
Follow-up relied on patient reports.
No standardized tools measured function, stiffness, or quality of life.
The report does not demonstrate cartilage regrowth or establish that the combination works better.¹⁷

It is a preliminary clinical observation, not a reliable success-rate estimate for everyone with knee pain.

Overall Recovery Support

The appeal of the Wolverine Stack is easy to understand: people want an option that addresses a difficult recovery. A useful evaluation should ask:

What tissue or condition was actually studied?
Was the experiment performed in cells, animals, or people?
Was the same peptide formulation used?
Did the study measure healing, symptoms, or only a biological marker?

Answering those questions is more informative than counting how many potential benefits appear on a product page.

Wolverine Peptide Stack Results Timeline: What To Expect Week By Week

There is no validated Wolverine Stack recovery calendar. The published studies discussed here do not establish that users should experience particular benefits at weeks 1–2, 3–4, 5–8, or 8–12.

If you are comparing personal recovery accounts, use those time periods as checkpoints for evaluating the account—not as a dosing cycle or a prediction.

Weeks 1–2: Look for a Clear Starting Point

Diagnosis: Was the injury medically assessed?
Baseline: Were pain, range of motion, and activity limitations recorded?
Other changes: Did the person also start resting, change training, or begin treatment?

An early change in symptoms does not identify its cause.

Weeks 3–4: Separate Symptoms From Function

Symptoms: Did soreness or stiffness change?
Function: Can the person perform a previously limited task?
Evidence: Is the improvement documented beyond a general statement that they feel better?

Less discomfort does not, by itself, demonstrate that damaged tissue has healed.

Weeks 5–8: Look for Consistency

Repeatability: Is improvement sustained across normal daily activities?
Rehabilitation: What other care or exercise progression occurred?
Setbacks: Does the account include flare-ups and adverse experiences?

This period is not an established milestone for peptide-driven repair.

Weeks 8–12+: Ask What Was Actually Verified

Follow-up: Was there a clinician’s assessment?
Durability: Did improvement persist?
Attribution: Could ordinary healing or other treatment explain the outcome?

Persistent or worsening symptoms warrant reassessment, rather than simply extending an online protocol.

🗣️ How Much Weight Should You Give Reviews?

Reviews can describe an experience. They usually cannot isolate the effects of one product. Give more weight to accounts that explain the diagnosis, concurrent treatments, follow-up, and setbacks; be skeptical of guaranteed timelines and before-and-after claims without context.

Wolverine Stack Dosage: What Should You Know?

No well-established human dosing regimen for the commercial BPC-157/TB-500 combination emerges from the evidence reviewed here. A vendor’s recommended cycle and a research protocol answer different questions.

What Affects How a Dose Is Interpreted?

Identity: Full-length thymosin beta-4 and its fragments are different materials.
Amount: Total milligrams in a blend do not necessarily equal milligrams of each peptide.
Concentration: Vial content and concentration after preparation are different measurements.
Route: Oral, topical, intravenous, and other administration routes cannot be assumed equivalent.
Study population: An animal dose should not be copied into a personal human regimen.

BPC-157 vs TB-500 Dosing Considerations

A pharmacokinetic study examined BPC-157 in rats and dogs and reported a short elimination half-life after the routes tested. It also found different intramuscular bioavailability between species. These results do not establish a human dosing frequency.¹⁸

TB-500 metabolism research likewise does not establish how often a person should take the compound. A detectable metabolite is not the same as a demonstrated therapeutic effect.¹⁰

Beginner vs Advanced Wolverine Stack Protocols

“Beginner” and “advanced” are online protocol labels, not validated medical categories. Experience with injections does not resolve uncertainty about efficacy, interactions, or long-term safety.

👉 Our Wolverine Peptide Stack dosage guide discusses this topic in more detail. Additional background:

How To Use the Wolverine Peptide Blend: What To Check First

Before considering any protocol, establish what the product is, what evidence applies to it, and what professional guidance is available. The checklist below is for evaluating information; it is not an injection or preparation protocol.

Step 1: Confirm What Is in the Blend

Ingredient identity: The precise peptide name and sequence, where available.
Individual amounts: BPC-157 and TB-500 content listed separately.
Batch information: A report that matches the actual lot.
Intended use: Clear labeling, without treating “research use only” as permission for self-administration.

Step 2: Understand the Goal

A diagnosed tendon tear, nonspecific knee pain, and post-training soreness are different problems. Start with a clear diagnosis and discuss established options with a licensed clinician.

Step 3: Treat Preparation and Storage as Product-Specific

Do not improvise dilution, sterility, storage duration, or injection instructions from a generic internet guide. A research-product label is not a substitute for appropriate clinical and pharmacy guidance.

Step 4: Set Realistic Expectations

Do not assume the blend will resolve the injury.
Do not interpret a short-term symptom change as proof of tissue repair.
Do not delay assessment of persistent pain, weakness, swelling, or loss of function.

Step 5: Evaluate Quality Claims Carefully

A purity result answers a narrower question than “Is this safe to inject?” Check whether identity, content, sterility, and endotoxins were actually assessed; do not assume one reported percentage covers them all.

Step 6: Speak With a Qualified Professional

Discuss your diagnosis, medications, medical history, and the uncertainty around the product. For a research-only vial, supplier reassurance should not be the basis for a personal treatment decision.

What Human Studies Tell Us About Safety

Some human peptide studies exist, but they involve different compounds, routes, and populations. Their limitations are worth seeing together.

BPC-157 infusion pilot: A study involving only two adults reported no adverse effects during its short observation period. That sample cannot establish general or long-term safety.¹⁹
Recombinant thymosin beta-4: A phase I study enrolled healthy volunteers in single- and multiple-dose intravenous groups. Adverse events were mild to moderate, with no serious adverse events reported. It tested a defined recombinant product, not an online Wolverine blend.²⁰
Thymosin beta-4 eye drops: A 72-person dry-eye trial found improvements in some secondary outcomes, but neither primary endpoint differed significantly from placebo. An eye-drop trial is not evidence for injected TB-500 in tendon recovery.²¹
Another ophthalmic trial: An 18-person neurotrophic keratopathy study reported healing in 6 of 10 treated participants versus 1 of 8 receiving placebo at four weeks; that comparison did not meet the conventional statistical-significance threshold. Later outcomes were encouraging, but the trial concerned a specific eye condition and formulation.²²

Evidence takeaway: A promising result belongs to the compound, route, condition, and population actually studied. It should not be transferred automatically to every product carrying a related peptide name.

The FDA has identified concerns involving immune reactions, aggregation, peptide-related impurities, and limited safety information for BPC-157 and the thymosin beta-4 fragment. These uncertainties deserve attention even when a seller provides a certificate of analysis.²³

Where To Buy the Wolverine Peptide Stack

If you are comparing research suppliers, evaluate the documentation before price or marketing claims.

Formula transparency: Can you identify the exact ingredients and amounts?
Traceable testing: Does the certificate match the batch, and can the laboratory or report be verified?
Scope of testing: What was measured, and what was not?
Clear handling information: Are storage and intended-use instructions available?
Realistic claims: Avoid promises of guaranteed healing, cartilage regrowth, or risk-free injections.
Total cost: Compare equivalent quantities and include shipping; a low price is not a quality assessment.

Our guide to the best places to buy the Wolverine Peptide Stack provides a starting point for comparing research suppliers. A supplier ranking does not establish clinical safety or effectiveness.

👉 View Our Recommended Wolverine Stack Sources

For more context, see our gray-market versus pharmacy-grade peptide discussion and Wolverine Stack price guide.

Frequently Asked Questions

What Is the Wolverine Peptide Stack Used For?

It is marketed and discussed for injury recovery, tendon and ligament support, muscle repair, and joint comfort. Those are reasons people investigate it, rather than established medical indications for the blend.

What Is the Best Wolverine Stack Dosage?

There is no evidence-based “best dose” for the commercial combination established by the studies discussed here. Vial ratios, administration routes, and study methods differ. Do not turn an animal experiment or online anecdote into a personal dosing plan.

How Long Does the Wolverine Peptide Stack Take to Work?

A reliable onset or recovery timeline has not been established for people using the blend. The week-by-week section above explains how to evaluate recovery accounts without treating them as predictions.

Is BPC-157 Better Than TB-500?

There is no established answer for human injury treatment. Different mechanisms and separate animal experiments do not amount to a clinical head-to-head comparison.

Can You Use BPC-157 and TB-500 Together?

They are sold together, but availability is not evidence that combining them is safer or more effective. The 2026 rat experiment discussed above did not demonstrate added benefit from the combination; it cannot establish a safe human protocol.¹¹

Is the Wolverine Peptide Stack Safe?

The evidence is insufficient to establish the blend’s overall safety. Questions include:

Product identity and impurities.
Immune reactions and peptide aggregation.
Preparation and injection risks.
Interactions and long-term effects.

FDA safety concerns and the limited scope of human studies are reasons to avoid describing these products as proven safe.²³

👉 Read our Wolverine peptide side effects guide and legal-status guide. Regulatory questions depend on the jurisdiction and intended use.

Is the Wolverine Stack Banned in Sport?

Under WADA rules, BPC-157 is prohibited at all times under S0. Thymosin beta-4 and derivatives such as TB-500 are prohibited at all times under S2.3. These restrictions extend beyond competition day.²⁴

Who Should Avoid the Wolverine Peptide Stack?

The available evidence does not identify a broadly safe group of self-directed users. Pregnancy, breastfeeding, significant medical conditions, cancer treatment, and concurrent medications require particular caution and individualized clinical advice. Do not infer safety for these groups from small studies of selected adults.

Our Wolverine Stack guide for women discusses related questions. Hormone or cycle-timing claims should be evaluated against actual human evidence.

Does Injecting Near an Injury Make It Work Better?

The studies cited here do not establish that self-injecting near an injury improves human outcomes. Claims about “local targeting” should not be inferred from cell-migration experiments or animal administration methods.

See our discussion of local versus systemic administration claims for background, rather than treating proximity to pain as an injection-site recommendation.

Can the Wolverine Stack Help With Tendon or Ligament Injuries?

Animal findings make these reasonable research questions. They do not establish that the blend heals human tears, avoids surgery, or replaces rehabilitation. Diagnosis and treatment planning should come first.

Explore the injury-specific discussions:

Final Thoughts

The Wolverine Peptide Stack brings together two compounds associated with tissue-repair research. The useful questions are specific: Which molecule was tested? In what model? With what outcome? And does that evidence apply to the product or claim being discussed?

Use the references below to examine those questions directly. For an actual injury, pair your reading with a proper assessment and a treatment plan grounded in your diagnosis.

References

Numbered references correspond to the superscript links in the article. Animal and laboratory studies are identified in the relevant sections; they should not be interpreted as clinical proof for a commercial blend.

Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551. PubMed. ↩
Esposito S, Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. doi:10.1002/dta.1402. PubMed. ↩
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. PubMed. ↩
Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066. PubMed. ↩
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y. PubMed. ↩
Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. doi:10.1038/s41598-020-74022-y. PubMed. ↩
Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. doi:10.1046/j.1524-475x.2003.11105.x. PubMed. ↩
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. doi:10.1096/fj.03-0121fje. PubMed. ↩
Qiu P, Kurpakus-Wheater M, Sosne G. Matrix metalloproteinase activity is necessary for thymosin beta 4 promotion of epithelial cell migration. J Cell Physiol. 2007;212(1):165-173. doi:10.1002/jcp.21012. PubMed. ↩
Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. doi:10.1016/j.jchromb.2024.124033. PubMed. ↩
Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. doi:10.52312/jdrs.2026.2951. PubMed. ↩
Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-2499. doi:10.2147/dddt.s82030. PubMed. ↩
Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/s0736-0266(03)00110-4. PubMed. ↩
Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi:10.1002/jor.21107. PubMed. ↩
Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109-1117. doi:10.1002/jor.20089. PubMed. ↩
Park JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020;26(25):2971-2981. doi:10.2174/1381612826666200523180301. PubMed. ↩
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PubMed. ↩
He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi:10.3389/fphar.2022.1026182. PubMed. ↩
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PubMed. ↩
Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. doi:10.1111/jcmm.16693. PubMed. ↩
Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-884. doi:10.2147/opth.s80954. PubMed. ↩
Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2023;24(1):554. doi:10.3390/ijms24010554. PubMed. ↩
US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Accessed September 11, 2026. FDA source. ↩
World Anti-Doping Agency. The Prohibited List. Accessed September 11, 2026. WADA source. ↩